Rpi-856 C
Rpi-856 C is an Aspartic protease inhibitor, with an IC50 of 5.5 nM against HIV-1 protease, 9.2 nM against HTLV-I protease, 2.0 μM against Cathepsin D, and 4.8 μM against Pepsin. Rpi-856 C is produced by the Streptomyces strain AL-322. Rpi-856 C does not inhibit chymosin, trypsin, chymotrypsin, papain, bromelain, thermolysin, prolyl endopeptidase, carboxypeptidase A or carboxypeptidase B. Rpi-856 C can be used in the research of acquired immunodeficiency syndrome (AIDS) and related diseases, as well as HIV infection.
For research use only. We do not sell to patients.
- CAS No.: 157381-55-0
- Formula: C39H56N6O10
- Molecular Weight:768.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
Cathepsin D 2.0 μM (IC50) |
HIV-1 Protease 5.5 nM (IC50) |
Microbial Metabolite |
In Vitro
Rpi-856 C (3 h) potently inhibits recombinant HIV-1 protease derived from Escherichia coli MM294 (DE3)/pHIV7004, with an IC50 value of 5.5 nM[1].
Rpi-856 C inhibits recombinant HTLV-I protease derived from Escherichia coli MM294 (DE3)/pHTI7707, with an IC50 value of 9.2 nM[1].
Rpi-856 C inhibits bovine cathepsin D with an IC50 value of 2.0 μM[1].
Rpi-856 C exhibits inhibitory activity against porcine pepsin, with an IC50 value of 4.8 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 157381-55-0
-
Molecular Weight 768.90
-
Formula C39H56N6O10
-
Sequence
V-{Gly(2-(3,5-dihydroxyphenyl))}-L-{2-oxo-4-phenyl-3-aminobutanoyl}-VV
-
Sequence Shortening
Val-{Gly(2-(3,5-dihydroxyphenyl))}-Leu-{2-oxo-4-phenyl-3-aminobutanoyl}-Val-Val
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Rpi-856 C
- 157381-55-0
- HIV Protease
- Cathepsin
- Endogenous Metabolite
- Escherichia coli MM294 (DE3)/pHIV7004
- bovine cathepsin D
- HTLV-I protease
- acquired immunodeficiency syndrome
- porcine pepsin
- Streptomyces sp. AL-322
- aspartic protease
- human immunodeficiency virus infection
- Escherichia coli MM294 (DE3)/pHTI7707
- HIV-1 protease
- Inhibitor
- inhibitor
- inhibit